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feasibility of combined neuroprotection in patients with AIS convincingly are sub-
stantiated by leading Ukrainian neurologists. The aim is to evaluate the economic
feasibility of combined regimens of neuroprotection compared with the
traditional. METHODS: Analysis of the results of comparative clinical trial of three
neuroprotective regimens therapy of patients with moderate and severe AIS: tra-
ditional  citicoline (1 regimen); traditional  citicoline  actovegin (2 regimen); 3
regimen: traditional (pentoxifylline, heparin, acetylsalicylic acid, mannitol) (S. M.
Vinychuk, O. A. Pustova, V.O. Mokchnach et al., 2008) was carried out. Cost-effec-
tiveness analysis was used. Using a decision tree comparing the economic burden
of the three regimens for one year was carried out. RESULTS: The number of pa-
tients who recovered completely after three months were used as efficacy. The
efficacy for 1, 2 and 3 regimens were respectively 29.6%, 38.9% and 23.3%. Direct
costs of the treatment regimens were $ 1.015; $ 1.186; $ 617 for 1, 2 and 3 regimens,
respectively. Incremental cost-effectiveness ratio (ICER) for 1 and 2 regimens were
respectively $6.317, $3.647. The economic burden per one patient for one year were
$ 7006; $ 6511; and $ 6930 for 1, 2 and 3 regimens, respectively. CONCLUSIONS: The
use of regimen 1 and regimen 2 provides greater efficacy and needs greater cost.
With the forecast for one year and taking into account the indirect costs the neu-
roprotective regimen with combination of two drugs (regimen 2) has economic
advantages.
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OBJECTIVES: The prevalence of atrial fibrillation (AF) in France approaches one
million people. The major complication associated with AF is stroke. Current anti-
coagulation options for stroke prevention increase the risk of hemorrhages. Objec-
tives were to estimate the 2-year cumulative incidence and costs of hospitaliza-
tions for strokes and hemorrhages in adults hospitalized for AF and eligible for
stroke prevention. METHODS: Data for patients with an AF-related hospitalization
in 2008 were extracted from the French Hospital National Database (PMSI). Risk
scores (i.e.CHADS2; range:0–6) were calculated from 2006–2008 data. Patient eligi-
ble for stroke prevention with anti-coagulants (i.e.CHADS21) were selected for
the follow-up analysis. Strokes and hemorrhages hospitalizations were identified
according to ICD-10 codes. Strokes severity was based on rehabilitation length and
death. Cumulative incidence was calculated by the number of new hospitalizations
during the 2-year period divided by the number of patients. Mean hospital costs
were calculated from to the 2011 National Hospital Tariff for acute and rehabilita-
tion care. RESULTS: A total of 61,582 AF patients were identified. Mean age was
75.0(11.0) years old and mean CHADS2 was 1.90(0.99). 2-year cumulative inci-
dences of any strokes and hemorrhages were 3.21% (ischemic/60%; hemorrhagic/
24%; unspecified/16%) and 5.31% (gastro-intestinal/26%; intracranial/5%; others/
69%), respectively. Mean costs of ischemic and hemorrhagic strokes were €4,848
and €7,183 (mild), €10,909 and €14,298 (moderate), €29,065 and €29,701 (severe) and,
€6,035 and €4,590 (fatal), respectively. Mean costs of hemorrhages were €3,601 and
€7,331 for gastro-intestinal and intracranial localizations and, €3,941 and €2,552 for
others major and non-major hospitalized bleeds. CONCLUSIONS: Frequencies and
cost of hospitalized hemorrhages appear important to be taking into account in the
global burden of AF. This data should be useful for future French pharmacoeco-
nomic evaluations of new oral anti-coagulants. Thus, this real world data study
may be helpful to assess consistency of patients’ features within recent published
clinical trials.
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OBJECTIVES: To estimate the health care resource utilization and direct costs of
cardioembolic stroke in patients treated in public hospitals of the Region of Madrid
(Spain). METHODS: An observational, prospective study was performed in 5 Neu-
rology services from hospitals in the Region of Madrid, 2 with stroke units (SU) and
3 without stroke units (wSU). Patients with a diagnosis of cardioembolic stroke with
48-hours were recruited in a 4-month period in 2012. Patients’ socio-demo-
graphic, clinical data: disability (modified Rankin scale, mRs), hospital stay and
mortality; complications and health care resource utilization (hospitalisation, in-
patient and at discharge rehabilitation, medication, laboratory tests and specific
therapeutic interventions) were collected. Unitary costs were obtained from na-
tional health care database and the Spanish Catalogue of Medicinal Products (€,
year 2012). RESULTS: Preliminary results from 76 patients (25 SU, 51 wSU) were:
mean age, 74.21.42; 64.5% female; mean mRs at discharge, 2.020.20; non-valvu-
lar atrial fibrilation was the main cause of cardioembolic stroke (28.9%); mean
length of stay, 10.11.14 days; mortality, 5.3%; 42 patients (68.4%) needed in-pa-
tient rehabilitation and 48 patients (63.2%) needed rehabilitation after hospital
discharge; 22 patients (28.9%) suffered hospital complications (63.6% of them suf-
fered infections, 27.3% cardiovascular complications and 59.1% others). Health care
resource utilization differences between SU and wSU hospitals were found in:
length of stay (7.21.26 days, SU; 11.61.55 days, wSU; p-value0.014) and specific
therapeutic interventions (41.7%, SU; 8.0%, wSU; p-value0.001). The overall
4-month cost per patient was 13,647€ (49.2%, hospital stay; 24.8%, rehabilitation at
discharge). CONCLUSIONS: Cardioembolic stroke imposes significant economic
burden for the Public Health System in the Region of Madrid. Key cost drivers were
hospital stay and patients’ rehabilitation at discharge. Patient management in SU
hospitals was associated with more specific therapeutic interventions and shorter
hospital stay than hospitals wSU.
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OBJECTIVES: To evaluate the annual acute and long-term hospitalizations cost of
MR from a French National Payer perspective. METHODS: A 12 months retrospec-
tive population-based study was conducted using the 2009–2010 French Medical
Information System (PMSI). This exhaustive database covers all public and private
hospitals in France and it is based on standardized hospital discharge reports. Each
patient is identified using a unique anonymous identification number allowing a
longitudinal follow-up. Extracted variables included patients’ demographics, out-
comes, acute hospital and post-discharge resource utilizations. RESULTS: 19,868
MR patients were identified and analyzed in two sub-groups depending on their
therapeutic management. In the surgical group (n4,099), the index hospitaliza-
tion length of stay was 17 days, 77% of patients were discharged to a rehabilitation
facility and the average re-hospitalization rate was of 33% over a 6 month period.
The average total cost per patient was €22.152. In the non-surgical group
(n15,769), patients were hospitalized on average 3.1 times over 12 months with an
average length of stay of 7.7 days. Among those patients, 24% were admitted to a
rehabilitation facility (on average 1.5 times) with an average length of stay of 27.9
days. The average total cost per patient was €12.177, varying between €9.957 to
€13.538, without and with heart failure respectively. Detailed analysis showed 2 to
3 times higher costs in the 9th and 10th percentiles. By sub-group, the average cost
of the 10th percentile was €50.268 for the surgical group and €36.503 for the non-
surgical group. CONCLUSIONS: The total observed cost in this population was €283
million over 12 months. Significant differences were observed in cost and resource
used between the surgical and non-surgical groups and depending on type of sur-
gery or presence of heart failure within each subgroup. This is the first study re-
porting hospital costs associated to MR in France.
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OBJECTIVES: Cardiovascular diseases (CVDs) imposes a burden to society in terms’
of mortality, morbidity and economic losses. The aim of this study was to estimate
the cost of CVDs in Serbia in 2009 from the perspective of the society. METHODS:
For the purpose of the study CVD was defined by the International Classification of
Disease 10 revision, as the following diagnosis: hypertension, coronary heart dis-
ease, cardiomyopathy, heart failure and cerebrovascular disease. The prevalence,
top-down method was used to quantify the annual cardiovascular costs. Produc-
tivity losses were estimated using the human capital approach and the friction cost
method. Data were collected from Serbian Health Insurance Fund and National
Public Health Institute “Batut”. A discount rate of 5% was used to convert all future
lifetime earnings into the present value. RESULTS: The total direct costs of CVD in
2009 were € 400 million. The majority of total costs (€ 514.3 million) were for:
medication (29.94%), hospital days (28.97%) and hospital inpatient care – surgical
and diagnostic interventions (17.84%). Indirect costs (mortality and morbidity) ac-
counted for 22.15% of total costs. The results showed that more than half a million
working days were lost due to incapacity resulting from CVDs. The results were
robust to a change in20% of volume or the unit price of all direct and indirect cost
and to discount rate 2% and 10%. CONCLUSIONS: The total CVD in 2009 repre-
sented approximately 1.8% of the Serbian gross domestic product. The results of
study would be valuable to health policy makers to bridge the gap between in-
vested resources and needs, in order to improve cardiovascular disease outcomes.
PCV32
THE COST OF DIABETES COMPLICATIONS IN BELGIUM
Lamotte M, Chevalier P
IMS Health, Vilvoorde, Belgium
OBJECTIVES: The risk of cardiovascular risk is higher in patients with diabetes but
what with the cost of this complication? The aim of this study was to compare the
cost of cardiovascular events in patients with and without diabetes in Belgium.
METHODS: Cost of cardiovascular events among hospitalized patients were esti-
mated using the longitudinal IMS Hospital Disease Database (2008), including data
on 34.3% of Belgian hospital beds, combined with Belgian population data. Stays
were identified based on ICD-9 or DRG coding. Cardiac disease included myocardial
infarction (MI; ICD-9:410), angina (ICD-9: 413) and heart failure (ICD-9: 428). Cere-
brovascular disease (CVD) was defined as stroke (APR-DRG:045;046) and Transient
Ischemic Attack (TIA; DRG:047). Diabetes was defined with the ICD-9 codes 249 and
250. Cost comparisons were made using a Wilcoxon non-parametrical test.
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RESULTS: An MI in a diabetic patient was 35% more expensive compared to a non
diabetic (€7,483 vs. €5,549; p0.001). In angina and heart failure the difference was
less pronounced, nevertheless the cost was respectively 22% and 13% higher (an-
gina: €2,570 vs. €2,101; p0.01, heart failure: €8,776 vs. €7,757; p0.001). Stroke was
8% more expensive and TIA 17% more expensive (stroke: €9,508 vs. €8,804; TIA:
€4,802 vs. €4,109; both p0.001). Reason for this higher cost is the longer length of
stay varying from 1 day in angina to 3 days in MI. The percentage of women was
higher in the diabetic group (50% vs. 47%; p0.05) and diabetic patients were on
average 1.8 years older (72.8 vs. 71.0; p0.01). A regression analysis learned that age
was the most important cost driver for all outcomes and diabetes was an indepen-
dent driver for MI and stroke. CONCLUSIONS: Patients with diabetes do not only
have a higher risk of cardiovascular events, in case they have an event this event is
significantly more expensive.
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OBJECTIVES: To study the economic burden of cardiovascular diseases (CVD) in
Russian Federation in 2006-2009. METHODS: The economic burden was calculated
by the cost of illness method. The calculations included direct costs of health care
system and indirect costs, associated with premature death in working age and
disability. We used official statistics of health care resources utilization, associated
with CVD (hospital days, outpatients visits, emergency visits), the results of phar-
macoepidemiological surveys of CVD, mortality and disability statistics in Russia in
2006-2009. RESULTS: The total economic burden of CVD increased from 20.6 bil-
lions of euro in 2006 till 26.6 billion of euro in 2009 what was equal to 3.1-2.8% of
GDP of Russian Federation. The increasing of the burden was mainly caused by the
price increasing and in some degree by the increasing of PCI in CHD patients in
recent years. Direct costs accounted 21.3% of total cost of CVD (5.7 billions of euro),
indirect costs – 78.7% (20.9 billions of euro) in 2009. Indirect costs mainly consisted
of the GDP losses because of premature death of working age men. CHD repre-
sented 37.8%, cerebrovascular diseases 17.1 % and hypertension -10.8% of overall
CVD costs. In-hospital care represented 47.5% of direct costs, outhospital visits –
21.8%, medication – 20.7%, PCI – 4.1% and emergency care 4.1% of direct costs in
2009, respectively. CHD represented 45.3% of direct cost, because of large duration
of hospitalization and PCI costs. CONCLUSIONS: CVD is a big public health chal-
lenge in Russia. The results of economic burden assessment should help policy
makers evaluate policy impact and prioritize expenditures.
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OBJECTIVES: Acute coronary syndrome (ACS) is a major complication of the ath-
erosclerotic process that may lead to myocardial necrosis. It is a medical emer-
gency and requires immediate hospital admission. The aim of the present study
was to assess the epidemiology and economic burden of ACS in Turkey, where the
population is aging, incidence of cardiovascular diseases tend to increase, yet,
knowledge on ACS-related health expenditures are inconclusive. METHODS: For
this purpose, the 2008 data acquired from 28 hospitals of the Diagnose-Related
Group Project were evaluated, accounting for 6.5% of the population. Accordingly,
the number of hospitalized patients with an ACS diagnosis in 2008 was 102,677. The
majority of patients with ACS were 40 years of age, and thus, all statistical anal-
yses were limited to this age group. RESULTS: The rate of new ACS admissions was
calculated as 444 per 100,000. With the assumption (based on earlier published
work) that 1/3 of ACS patients failed to reach health care settings, the prevalence of
new ACS cases in the general population was estimated to be 666 per 100,000. The
average in-patient fatality rate was 29% (41% for females and 24% for males) among
the 40 years of age group. The economic burden of ACS in Turkey was
1,778,372,874 USD. The direct cost was 151,261,411 USD, whereas the indirect cost
was 1,364,742,497 USD. The cost due to the loss of public tax was 262,368,964 USD.
Medication costs, which are annually 590 USD per patient on average, encountered
a small percentage of total expenditures, compared with that of hospital services
and the loss of public tax. CONCLUSIONS: To prevent ACS, health policies targeting
risk factors should be emphasized in an effort to improve efficacy and efficiency of cost.
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OBJECTIVES: Germany reformed its hospital reimbursement scheme to service-
based payment to diagnosis-related groups. Hospitals in Germany might be more
cost-conscious in treating patients compared to the pre-reform period. This study
identified the post-reform individual-level direct medical costs and costs over time
of several cardiovascular diseases (CVDs), including myocardial infarction (MI),
heart failure (HF), peripheral artery diseases (PADs), and stroke, from the perspec-
tive of Statutory Health Insurance in Germany. METHODS: A systematic review
(January 2003 to May 2012) was conducted in Pubmed, Embase, CRD, TIBORDER,
and German dissertation database to identify relevant English or German language
publications. RESULTS: The search identified 157 publications, of which 10 met the
predefined inclusion/exclusion criteria for review: 5 about MI, 2 about HF, 1 about
PAD, and 5 about stroke. The direct medical costs of MI were between € 11,672 -
12,372/patient in the 1st year after the event; 50-60% of the costs incurred in the
acute phase. During the 13-18 months after the event, the costs were estimated to
be € 981/patient. Direct medical costs of severe chronic HF were € 27,700/patient
annually. Direct medical costs of hospitalized PAD were € 7,674/patient in the 1st
year, including € 4,186 in the acute phase. In months 13-18, the costs were € 1,172/
patient. For stroke of all types, direct medical costs in the 1st year were € 11,408/
patient, half of which were incurred in the first 4 weeks after the event. For isch-
emic stroke, direct medical costs in the 1st year were € 17,864 - € 18,517/patient,
with 29% incurred in the acute phase. In the subsequent 4 years, annual direct
medical costs were € 5,479/patient. CONCLUSIONS: In Germany, treating CVDs
triggers substantial direct medical costs, especially in the acute phases. Hospital-
ization and rehabilitation are two major cost drivers.
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OBJECTIVES: To determine whether there are certain treatment patterns and cost
differences in CHD-patients treated with different nitrates. METHODS: Full data
sets of 4 Million patients from SHI of the years 2001 to 2011 were enrolled to identify
CHD-patients treated with different nitrates. Demographic data as well as resource
consumption were collected. Events related to CHD were identified. Based on this
data a Markov model was created to calculate length of stay on a treatment prin-
ciple, to calculate costs per treatment principle and to calculate the death rate due
to different nitrate treatments. For cost analysis, German SHI perspective was
chosen. Drug costs were taken from official price lists of 2012. Future costs were
discounted by 2.5%. Sensitivity analyses were conducted. RESULTS: More than 1
Million patient biographies were eligible, 14% were CHD-patients and 18,691
(1,85%) patients treated with nitrates were observed. 30 % were male, 20 % on
Isosorbidmononitrate (ISMN), 50% on Isosorbiddinitrate (ISDN) and 30 % on PETN.
Average starting age was 59.8 years on ISMN, 60 on ISDN and 57.8 on PETN. Demo-
graphics were comparable, with more patients living in Eastern Germany. Treat-
ment duration was 16.9 years on ISMN, 16.6 on ISDN and 17.0 on PETN. Mortality
rates were 2.5% under ISMN resp. ISDN and 1% under PETN. Total annual costs per
patient (excluding hospital costs) were €1,485,- for ISMN, €1,529,- for ISDN and
€1,158,- for PETN. PETN-patients receive less additional drugs for CHD, diuretics,
psychopharmacotherapeutics and further non-specified drugs. Further analyses
indicated that PETN patients are treated more often out-patiently. Sensitivity anal-
yses stated stability of the presented results. CONCLUSIONS: Treatment of CHD-
patients with PETN is less costly for SHI. Abdication of PETN due to current fictive
approval and higher drug costs – as published recently – will lead to prescription of
other nitrates and as consequence, higher costs will accrue.
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OBJECTIVES: To evaluate venous thromboembolism (VTE) rate and incremental
costs during hospitalization for total knee (TKA) and hip arthroplasty (THA) in
public and private health system. METHODS: Retrospective cohort study of pa-
tients undergoing elective TKA or THA in 2010. All reviewed charts were from
either one public or two private hospitals in São Paulo state, Brazil. Patients were
18 years old, and excluded from the study if antithrombotic drugs were used prior
to surgery. Costs were estimated based on hospitalization resource utilization de-
scribed in patients= chart. Costs are expressed in 2012 US$. RESULTS: From a total
of 233 patients, 215 were included: 121 (56.3%) TKA and 94 (43.7%) THA. A total of
203 (94.4%) patients received VTE prophylaxis, being enoxaparin the first choice in
201 (99%). VTE was suspected in 7 (3.3%) cases during hospitalization (4 TKA/3
THA). VTE was confirmed in two cases from private hospitals: one deep vein throm-
bosis (DVT) and one DVT/pulmonary embolism, both TKA. In the public setting
(N81), length of stay (LOS) and hospitalization average cost per patient were 4.9
(SD3.8) days and US$2,327.12, respectively, in non-VTE group (N79) while 13
(SD9.0) days and US$3,121.01 in suspected VTE group (N2). In the private setting
(N134), LOS and hospitalization average cost per patient were 5.1 (SD3.0) days and
US$14,006.28, respectively, in non-VTE group (N129), 15.7 (SD11.3) days and
US$22,006.33 in suspected VTE group (N3), and 22 (SD7.1) days and US$28,232.33
in confirmed VTE group (N2). CONCLUSIONS: In our study, VTE rate was 0.9%,
increasing four times the LOS and doubling hospitalization costs (US$ 14,226.05/
patient) for the private service when comparing to patients without event. LOS of
suspected patients was similarly extended in both health services yet with higher
hospitalization cost for the private setting.
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